These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 32631704)

  • 1. Sodium-glucose co-transporter-2 inhibitors: peculiar "hybrid" diuretics that protect from target organ damage and cardiovascular events.
    Sarzani R; Giulietti F; Di Pentima C; Spannella F
    Nutr Metab Cardiovasc Dis; 2020 Sep; 30(10):1622-1632. PubMed ID: 32631704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New anti-diabetic agents: major advances with unanswered questions.
    Sabouret P; Bocchino PP; Biondi-Zoccai G
    Rev Cardiovasc Med; 2020 Dec; 21(4):489-492. PubMed ID: 33387991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2i: beyond the glucose-lowering effect.
    Ni L; Yuan C; Chen G; Zhang C; Wu X
    Cardiovasc Diabetol; 2020 Jun; 19(1):98. PubMed ID: 32590982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the Sodium-Proton Antiporter (Exchanger) is a Plausible Mechanism of Potential Benefit and Harm for Drugs Designed to Block Sodium Glucose Co-transporter 2.
    McCullough PA; Kluger AY; Tecson KM; Barbin CM; Lee AY; Lerma EV; Rosol ZP; Kluger SL; Rangaswami J
    Rev Cardiovasc Med; 2018 Jun; 19(2):51-63. PubMed ID: 31032603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 inhibitors and renal function.
    Med Lett Drugs Ther; 2016 Jul; 58(1499):91-2. PubMed ID: 27403782
    [No Abstract]   [Full Text] [Related]  

  • 6. The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action.
    Lioudaki E; Androulakis ES; Whyte M; Stylianou KG; Daphnis EK; Ganotakis ES
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):215-225. PubMed ID: 28444472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
    Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
    Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition.
    Tsimihodimos V; Filippatos TD; Filippas-Ntekouan S; Elisaf M
    Curr Vasc Pharmacol; 2017; 15(2):96-102. PubMed ID: 27748201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.
    Carbone S; Dixon DL
    Cardiovasc Diabetol; 2019 May; 18(1):64. PubMed ID: 31138195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease.
    León Jiménez D; Cherney DZI; Bjornstad P; Castilla-Guerra L; Miramontes González JP
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1406-F1415. PubMed ID: 30066584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiorenal protection of sodium-glucose cotransporter 2 inhibitors beyond diabetes: news from the European Society of Cardiology Congress 2020.
    Ferrannini G
    Eur Heart J Cardiovasc Pharmacother; 2020 Nov; 6(6):341-342. PubMed ID: 32991694
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients.
    Xiang B; Zhao X; Zhou X
    Cardiovasc Diabetol; 2021 Apr; 20(1):78. PubMed ID: 33827579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis.
    Castellana M; Procino F; Sardone R; Trimboli P; Giannelli G
    Cardiovasc Diabetol; 2020 Jun; 19(1):87. PubMed ID: 32534590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decrease mortality in type II diabetes mellitus: glycemic and renal function control.
    Borghi C; Ventura F
    J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e13-e15. PubMed ID: 29538138
    [No Abstract]   [Full Text] [Related]  

  • 17. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Furtado RHM; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Lancet; 2019 Jan; 393(10166):31-39. PubMed ID: 30424892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.
    Inzucchi SE; Zinman B; Wanner C; Ferrari R; Fitchett D; Hantel S; Espadero RM; Woerle HJ; Broedl UC; Johansen OE
    Diab Vasc Dis Res; 2015 Mar; 12(2):90-100. PubMed ID: 25589482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
    Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.